BIOTRONIK SE & Co.KG
282 articles about BIOTRONIK SE & Co.KG
BIOTRONIK Enrolls First Patient Into BIO-CONDUCT, First IDE Trial to Study Use of Stylet-Driven Leads for Conduction System Pacing
BIOTRONIK, a global leader in the treatment of cardiac and vascular disease is pleased to announce the first patient enrollment in BIO-CONDUCT, an FDA approved investigational device exemption (IDE) trial examining the use of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area, a location for which the Solia S lead is not currently approved.
BIOTRONIK, Inc. Reaches Settlement with U.S. Department of Justice
BIOTRONIK, Inc. announced today that it has entered into a civil settlement with the U.S. Department of Justice, the U.S. Attorney's Office for the Central District of California, and the U.S. Department of Health and Human Services, Office of Inspector General, to resolve historical claims of alleged overuse of paid consultants to train field personnel and limited instances of excessive customer meals and travel.
Latest Study Shows New Algorithm Can Predict Heart Failure Hospitalizations
BIOTRONIK announced the results from a new study published in EUROPACE this week confirming that heart failure decompensation can be predicted early when monitored using an algorithm that combines existing remote monitoring trends and baseline risk stratification.
BIOTRONIK's Implantable Cardiac Monitor Receives Prestigious Industry Award
In association with Heart Rhythm 2021, BIOTRONIK announced that the latest implantable cardiac monitor, BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range of innovation and customer value criteria.
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here’s a look.
FDA Clears Fever-Detecting Vital Data Sensor in New Cardiac Monitor
BIOTRONIK today announced FDA clearance and availability of the Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new BIOMONITOR IIIm injectable cardiac monitor (ICM), as shown in a published case report 1 .
New Alliance Maps the Way in Electrophysiology
A New Strategic Alliance Between BIOTRONIK, A Leader In Cardiac Rhythm Management, and Acutus Medical, Electrophysiology Innovator, Expected to Offer More Efficient and Effective Diagnosis and Treatment for Arrhythmia Patients [20-May-2020] CARLSBAD, Calif. and BERLIN , May 20, 2020 /PRNewswire/ -- Acutus Medical and BIOTRONIK today announced a new alliance to p
BIOTRONIK's Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years
Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to Outperform Abbott's Xience
BIOTRONIK, Inc. Appoints David Hayes, MD, as Chief Medical Officer
BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer
Prix Galien Selects BIOTRONIK's PK Papyrus Covered Coronary Stent as Award Finalist
PK Papyrus Stent Delivers Emergency Treatment for Acute Coronary Artery Perforations
BIOTRONIK Receives FDA Clearance on Next-Gen Injectable Cardiac Monitor: BIOMONITOR III
BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatment.
Late-Breaking Data at EuroPCR: BIOTRONIK's Orsiro Demonstrates Unique Benefits in Small Vessels
A Subgroup Analysis of the BIO-RESORT RCT Three-Year Data Showed Significant Differences in Efficacy in Favor of Ultrathin Strut Orsiro [21-May-2019] PARIS and BUELACH, Switzerland , May 21, 2019 /PRNewswire/ -- Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion re
Focusing on Women: BIOTRONIK Launches Study to Understand the Impact of ICDs in NICM Patients
BIO-LIBRA Study Aims to Break the Tradition of Underrepresentation of Women in Heart Disease Studies
US Physicians Now Treating Patients with BIOTRONIK's Ultraslim Acticor DX Devices
New Hybrid ICDs Feature Increased Longevity, Smooth BIOshape and Simplified DF4 Header Configuration
BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US
Lifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations
InfoBionic Signs BIOTRONIK as Exclusive U.S. Distributor for MoMe® Kardia
InfoBionic today announced an exclusive, strategic agreement with medical device manufacturer BIOTRONIK for U.S. distribution of InfoBionic’s proprietary MoMe® Kardia system, effective immediately.
CORRECTING and REPLACING InfoBionic has Entered into an Exclusive Distributorship with BIOTRONIK for MoMe® Kardia in the U.S.; Expects Significant Nationwide Growth
NFOBIONIC HAS ENTERED INTO AN EXCLUSIVE DISTRIBUTORSHIP WITH BIOTRONIK FOR MOME® KARDIA IN THE U.S.; EXPECTS SIGNIFICANT NATIONWIDE GROWTH
BIOTRONIK Advances Arrhythmia Detection and Diagnosis with MoMe Cardiac Monitor in the US
Industry's Only Full Disclosure External Cardiac Monitor Provides Immediate Near Real-Time Data
Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US
Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology.
BIOTRONIK Release: CASTLE-AF Results Published in the New England Journal of Medicine, Showing Mortality Reduction for Heart Failure Patients
This reduction was observed when compared to patients treated with the pharmacological therapy recommended by current guidelines.